Ignite Creation Date:
2024-05-06 @ 8:19 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06334367
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-03-28
First Post:
2024-03-11
Brief Title:
Prophylaxis of Graft-versus-host Disease With Anti-CD25 Antibody in Patients Underwent HSCT
Sponsor:
Wang Xin
Organization:
Shandong Provincial Hospital
Study Overview
Official Title:
The Study of Anti-CD25 Antibody for Prophylaxis of GVHD in Patients Underwent Haploid Transplantation Conditioning With Low-dose ATG
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The risk of Graft-versus-host DiseaseGVHD is significantly associated with the mortality rate of patients undergoing allogeneic hematopoietic stem cell transplantation The occurrence of GVHD increases the hospitalization rate and economic burden of patients In order to explore better methods for controlling GVHD we designed a clinical trial using CD25 monoclonal antibody for GVHD prevention Our previous studies have shown that reduced-dose anti-thymocyte globulinATG in the conditioning regimen can achieve the same effect as full-dose ATG Here we try to explore the preventive effect of CD25 antibody on acute and chronic GHVD under low-dose ATG pretreatment condition
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None